FDA Approves Durvalumab / Imfinzi for Resectable NSCLC Non-Small Cell Lung Cancer

In this video, we cover the FDA's recent approval of durvalumab (Imfinzi) for the treatment of resectable non-small cell lung cancer (NSCLC). Approved on August 15, 2024, this treatment combines durvalumab with platinum-based chemotherapy as a neoadjuvant therapy and continues with durvalumab alone as adjuvant therapy post-surgery.

See more on this topic at OncologyTube: https://oncologytube.com/fda-approves...

The approval is based on findings from the AEGEAN trial (NCT03800134), which demonstrated significant improvements in event-free survival (EFS) and pathological complete response (pCR) in patients treated with durvalumab compared to placebo. Key data from the study includes:

EFS: Median not reached in the durvalumab arm vs. 25.9 months in the placebo arm (HR 0.68, p=0.0039)
pCR: 17% in the durvalumab arm vs. 4.3% in the placebo arm.
This video will also outline the recommended dosages, safety profile, and common adverse reactions, providing oncologists with essential insights into the new treatment strategy for NSCLC.

#Durvalumab, #Imfinzi, #LungCancerTreatment, #FDAApproval, #Oncology, #NeoadjuvantTherapy, #AdjuvantTherapy, #AEGEANTrial, #NonSmallCellLungCancer, #CancerResearch, #Oncologists